Volume 16

  • No. 4 December 2022
    In this issue...

    • Biopharma deals of 2022

    • Exploring the cell and gene landscape

    • Uncovering a new generation of microbial-based therapeutics

    • Dealmaking for immuno-inflammatory diseases

  • No. 3 September 2022
    In this issue...

    • Oncology’s highest-value deals: top ten

    • Mergers and acquisitions in CNS diseases

    • Big pharma dominates antibody dealmaking

    • Biopharma dealmaking in 2022 so far

  • No. 2 June 2022
    In this issue...

    • Small-molecule drug discovery accelerated by artificial intelligence

    • Infectious disease dealmaking refocuses

    • The rise of targeted protein degradation

    • RNAi therapeutics back on the menu

  • No. 1 March 2022
    In this issue...

    • Molecular diagnostics: exploring financial and partnering trends

    • How is the oncology dealmaking landscape shaping up?